Next Article in Journal
Structure-Activity Relationships Based on 3D-QSAR CoMFA/CoMSIA and Design of Aryloxypropanol-Amine Agonists with Selectivity for the Human β3-Adrenergic Receptor and Anti-Obesity and Anti-Diabetic Profiles
Next Article in Special Issue
Design and Efficacy of Nanogels Formulations for Intranasal Administration
Previous Article in Journal
Antioxidant and ACE Inhibitory Activity of Enzymatic Hydrolysates from Ruditapes philippinarum
Previous Article in Special Issue
Nanotechnological Strategies for Protein Delivery
Article Menu
Issue 5 (May) cover image

Export Article

Open AccessReview
Molecules 2018, 23(5), 1190;

Peritoneal Carcinomatosis Targeting with Tumor Homing Peptides

Laboratory of Cancer Biology, Institute of Biomedicine, Centre of Excellence for Translational Medicine, University of Tartu, Ravila 14b, Tartu 50411, Estonia
Cancer Research Center, Sanford-Burnham-Prebys Medical Discovery Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
Center for Nanomedicine and Department of Cell, Molecular and Developmental Biology, University of California, Santa Barbara, CA 93106, USA
Author to whom correspondence should be addressed.
Academic Editors: Sanjay Garg and Usha Y Nayak
Received: 19 April 2018 / Revised: 8 May 2018 / Accepted: 10 May 2018 / Published: 16 May 2018
(This article belongs to the Special Issue Targeted Drug Delivery and Nanocarriers)
Full-Text   |   PDF [658 KB, uploaded 16 May 2018]   |  


Over recent decades multiple therapeutic approaches have been explored for improved management of peritoneally disseminated malignancies—a grim condition known as peritoneal carcinomatosis (PC). Intraperitoneal (IP) administration can be used to achieve elevated local concentration and extended half-life of the drugs in the peritoneal cavity to improve their anticancer efficacy. However, IP-administered chemotherapeutics have a short residence time in the IP space, and are not tumor selective. An increasing body of work suggests that functionalization of drugs and nanoparticles with targeting peptides increases their peritoneal retention and provides a robust and specific tumor binding and penetration that translates into improved therapeutic response. Here we review the progress in affinity targeting of intraperitoneal anticancer compounds, imaging agents and nanoparticles with tumor-homing peptides. We review classes of tumor-homing peptides relevant for PC targeting, payloads for peptide-guided precision delivery, applications for targeted compounds, and the effects of nanoformulation of drugs and imaging agents on affinity-based tumor delivery. View Full-Text
Keywords: homing peptide; peritoneal carcinomatosis; intraperitoneal chemotherapy; p32; neuropilin-1; integrins; hyaluronan homing peptide; peritoneal carcinomatosis; intraperitoneal chemotherapy; p32; neuropilin-1; integrins; hyaluronan

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Simón-Gracia, L.; Hunt, H.; Teesalu, T. Peritoneal Carcinomatosis Targeting with Tumor Homing Peptides. Molecules 2018, 23, 1190.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Molecules EISSN 1420-3049 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top